Form 4: Pfizer Director Buckley Receives Phantom Stock Units as Deferred Compensation

Director Mortimer J. Buckley acquired 8,999 phantom stock units of Pfizer Inc. as part of a deferred compensation plan.

Summary

• Mortimer J. Buckley, a director of Pfizer Inc., reported a transaction on April 24, 2025, where he acquired 8,999 phantom stock units.
• These units were granted pursuant to Pfizer's Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.
• Each unit represents one phantom share of Pfizer common stock.
• The price of the phantom stock units was $22.78.
• Following the transaction, Buckley beneficially owns 12,893.086 derivative securities.
• The units represent deferred director's compensation that will be settled in cash or common stock at Buckley's election after retirement from the Board of Directors.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed neutrally. The use of deferred compensation is a common practice, suggesting stability and alignment of interests.

Positives

• The acquisition of phantom stock units aligns the director's interests with the long-term performance of Pfizer.
• Deferred compensation plans can be tax-efficient for directors.

Future Outlook

The phantom stock units will be settled in cash or common stock upon Buckley's retirement from the Board of Directors, subject to his election.

Industry Context

Deferred compensation plans are a common practice for compensating non-employee directors in publicly traded companies, aligning their interests with shareholders and providing tax-efficient benefits.

Comparison to Industry Standards

• Many large pharmaceutical companies, such as Johnson & Johnson (JNJ) and Merck (MRK), utilize deferred compensation plans for their non-employee directors.
• The structure of Pfizer's plan, involving phantom stock units that convert to cash or stock upon retirement, is consistent with industry norms.
• The specific number of units granted and their valuation would be benchmarked against peer companies' director compensation packages to assess competitiveness.

Stakeholder Impact

• Shareholders may view the deferred compensation plan positively as it aligns director interests with long-term company performance.
• The plan has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Pfizer, Mortimer J. Buckley, phantom stock units, deferred compensation, director compensation, PFE, Form 4